Evidence map›Paper›PMID 38173192›Full record

ArticleBalkan medical journal2024

Exploring Regional Disparities in Heart Failure Epidemiology and Outcomes: A Comprehensive Study Across Geographical Regions in Türkiye.

Anıl Şahin, Tuğçe Çöllüoğlu, Ahmet Çelik, Naim Ata, Mehmet Birhan Yılmaz, Dilek Ural, Arzu Kanık, Mustafa Okan Ayvalı, Mustafa Mahir Ülgü, Şuayip Birinci

Abstract read
In one paragraph

Article in Balkan medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Epidemiology of heart failure in Türkiye.Turkish journal of medical sciences · 2024
    Article
  8. Outcomes of patients with heart failure in Türkiye.Turkish journal of medical sciences · 2024
    Article
  9. Burden of comorbidities in heart failure patients in Türkiye.Turkish journal of medical sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anıl ŞahinDepartment of Cardiology, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Türkiye.ORCID 0000-0003-3416-5965
Tuğçe ÇöllüoğluDepartment of Cardiology, Karabük University Faculty of Medicine, Karabük, Türkiye.ORCID 0000-0002-2227-6177
Ahmet ÇelikDepartment of Cardiology, Mersin University Faculty of Medicine, Mersin, Türkiye.ORCID 0000-0002-9417-7610
Naim AtaGeneral Directorate of Health Information Systems, Ministry of Health, Ankara, Türkiye.ORCID 0000-0001-6947-2821
Mehmet Birhan YılmazDepartment of Cardiology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0002-8169-8628
Dilek UralDepartment of Cardiology, Koç University Faculty of Medicine, Mersin, Türkiye.ORCID 0000-0003-0224-1433
Arzu KanıkDepartment of Biostatistics and Medical Informatics, Mersin University Faculty of Medicine, Mersin, Türkiye.ORCID 0000-0002-7068-1599
Mustafa Okan AyvalıGeneral Directorate of Health Information Systems, Ministry of Health, Ankara, Türkiye.ORCID 0000-0002-0116-5152
Mustafa Mahir ÜlgüGeneral Directorate of Health Information Systems, Ministry of Health, Ankara, Türkiye.ORCID 0000-0003-0825-1851
Şuayip BirinciRepublic of Türkiye Ministry of Health, Ankara, Türkiye.ORCID 0000-0001-8104-6198

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Heart failure (HF) is a common condition that affects 1-3% of the general population. Its prevalence exhibits notable international and intranational disparities, partly explained by socioeconomic status, religion, ethnic diversity, and geographic factors. A comprehensive understanding of the epidemiological symptoms of HF in different regions of Türkiye has yet to be revealed. Aims: To examine epidemiological data from 2016 to 2022, focusing on crucial patient characteristics and geographical regions, to determine the incidence and prevalence of HF in Türkiye across seven diverse geographical regions. Study Design: A nationwide population-based retrospective cohort study. Methods: The comprehensive National Electronic Database of the Turkish Ministry of Health was used in this study to obtain data that covers the whole Turkish population from January 1, 2016, to December 31, 2022. The International Classification of Diseases-10 (ICD-10) codes were used to identify adults with HF (n = 2,701,099) and associated comorbidities. Türkiye is divided into seven geographically distinct regions. Epidemiological characteristics and survival data of these regions were analyzed separately. All-cause mortality was set as the primary outcome. Results: In , the total estimated prevalence of adult patients with HF is 2.939%, ranging from 2.442% in Southeastern Anatolia to 4.382% in the Black Sea Region. Except for the Eastern Anatolia Region, the three most often reported comorbidities were hypertension, dyslipidemia, and anxiety disorders. The rates of prescribing guideline-directed medical therapy (GDMT) for HF and other medications varied significantly. GDMT prescription rates were lowest in the Eastern Anatolia Region (82.6% for beta-blockers, 48.7% for RASi, 31.8% for mineralocorticoid receptor antagonists, and 9.4% for SGLT2i). The Mediterranean and Aegean regions had the highest median N-terminal brain natriuretic peptide (NT-proBNP) levels of 1,990,0 pg/ml (518.0-6,636,0) and 1,441,0 pg/ml (363.0-5,000,0), respectively. From 2016 to 2022, 915,897 (33.9%) of 2,701,099 patients died. The Eastern Anatolia Region had the lowest all-cause mortality rate of 26.5%, whereas the Black Sea Region had the highest all-cause mortality rate of 35.3%. Conclusion: Our real-world analysis revealed geographic disparities in HF characteristics, such as decreased mortality in socioeconomically challenged regions. Higher stress susceptibility in developed regions may increase the likelihood of adverse outcomes.

Indexed as

Heart FailureHypertensionHumansRetrospective StudiesStroke VolumeTurkey

Identifiers

PMID38173192
PMCPMC10767779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.